APLM vs ARAY

APLM's Piotroski F-Score of 3/9 indicates weak financial health, with significant red flags in profitability, cash flow, and leverage. The company exhibits extreme negative profitability metrics, including a -124.8% operating margin and -380.13% ROE, despite a 380.8% YoY revenue growth. With no Altman Z-Score available and a current ratio of 0.97, liquidity concerns persist. The stock trades at a high Price/Sales of 6.15 and a negative forward P/E of -30.62, suggesting valuation is driven by speculative growth expectations rather than fundamentals. The 52-week price range of $3.66 to $42.12 reflects extreme volatility, and the 5-year return of -98.0% underscores long-term underperformance.

ARAY's Piotroski F-Score of 4/9 indicates weak financial health, with a critical debt-to-equity ratio of 2.90 and negative ROE of -70.32%, signaling significant operational and solvency concerns. Despite a 16.8% year-over-year revenue growth, the company remains unprofitable with a negative profit margin of -8.15% and erratic earnings performance, including a -650% YoY EPS decline. The stock trades at a deeply discounted price-to-sales of 0.10 and price-to-book of 0.82, but this reflects severe market skepticism due to persistent losses and high financial risk. Analysts have a target price of $2.52, implying a potential 580% upside, yet this is based on minimal coverage and no consensus, underscoring speculative risk. The lack of insider activity and technical bearishness further reinforce a high-risk profile.